Founded in 2007 by dermatologist Dr. Zein Obagi, the brand has carved out a distinct niche by distributing its serums, cleansers, and exfoliators exclusively through physicians and clinical professionals. This professional-grade distribution model has become a primary target for strategic buyers seeking resilient assets. Unlike mass-market over-the-counter products, physician-backed lines benefit from higher consumer trust and more predictable demand cycles.
Blackstone Prepares $2 Billion Exit for ZO Skin Health
Investment giant Blackstone is exploring the sale of medical-grade skincare brand ZO Skin Health, a move that could value the company at approximately $2 billion. The firm has tapped Citigroup and Raymond James to manage the process, though discussions remain in the early stages according to people familiar with the matter.
Blackstone and Citigroup have declined to comment on the potential divestment, while representatives for ZO Skin Health and Raymond James did not immediately provide a response. The pursuit of a sale reflects a broader trend among private equity firms looking to monetize assets in the high-growth clinical skincare sector.
Comments (0)
No comments yet. Be the first!